AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02908451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbGn-107
Description: Antibody Drug Conjugate
Study NCT02623920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab
Description: Brentuximab vedotin IV over 30 minutes on day 1.Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT02623920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine IV over 30-60 minutes on days 1-2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT02623920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT04454567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-H0731
Description: Participants will receive ABI-H0731 tablets orally once daily
Study NCT04454567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo to ABI-H0731 tablets orally once daily
Study NCT03582397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mirror Therapy
Description: Virtual reality mirror therapy (WiseMind) developed by Realiteer and delivered via Oculus Rift virtual reality platform.
Study NCT00844220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT/MR
Description: CT/MRI-directed clinical management strategy
Study NCT00844220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization
Description: Standard clinical management directed by conventional coronary angiography
Study NCT02180672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Fluticasone
Description: One spray per nostril, per day.
Study NCT02180672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One spray per nostril, per day.
Study NCT04454567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NrtI
Description: Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert
Study NCT04454567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NrtI
Description: Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert
Study NCT01605331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sustained-release recombinant human GH (SR-rhGH)
Study NCT01265667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: orally q12h
Study NCT01265667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally q12h
Study NCT01120899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants take 100 mg minocycline pills twice daily for 24 months.
Study NCT02625376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resvega
Description: Dietary supplementation with Resvega BD
Study NCT02625376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans-Resveratrol
Description: Dietary supplementation with resveratrol 250 mg BD
Study NCT02625376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dietary supplementation with a placebo BD
Study NCT02948426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Monocytes + ACTIMMUNE + SYLATRON
Description: The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).
Study NCT04374422 — intervention group
Intervention type: BEHAVIORAL
Intervention: fsfi survey
Description: sexual behavior Questionaire
Study NCT01595841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 3 mg po od loading dose for two days, then 2 mg po od for thirty days
Study NCT02569541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium fusidate
Study NCT01135264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur \& Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
Study NCT01135264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CMBT
Description: We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
Study NCT00924586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-1101
Description: Placebo for one minute IV
Study NCT05479227 — intervention group
Intervention type: PROCEDURE
Intervention: Management of bile duct injury
Description: There are different options for BDI management, we analyzed their utilization and results
Study NCT00924586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-1101
Description: 0.125 mg/kg for one minute IV
Study NCT01493596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CPP-115
Description: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
Study NCT02256033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: One 40 mg-tablet administered on Day 1
Study NCT02572648 — intervention group
Intervention type: OTHER
Intervention: Brain Imaging (Neuroimaging)
Description: Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.~Total time in scanner will be approximately 53 minutes.
Study NCT02459964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Nasal Spray
Description: Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h)
Study NCT02459964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone Hydrochloride
Description: Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).
Study NCT02459964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.
Study NCT02459964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone Call
Description: Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.
Study NCT02485964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: One time blood draw at time of consent. Blood will be stored until all subjects have been enrolled and then the enzyme-linked immunospot (ELISPOT) assay will be done to measure the antigen-specific interferon secretion.
Study NCT02572648 — intervention group
Intervention type: OTHER
Intervention: Cognitive Function Assessment
Description: Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 \& 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).
Study NCT01655446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
Study NCT01655446 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
Study NCT00831597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 120 mg/m2 IV, Days 1, 2 of Cycles 1-6
Study NCT00831597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 IV, Day 1 of Cycles 1-6
Study NCT04196985 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
Study NCT04196985 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
Study NCT06022848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occipital nerve stimulator
Description: Quantitative sensory testing
Study NCT01456780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol/tobramycin
Description: Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
Study NCT01456780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol
Description: Eye drops, 1 drop twice a day for 4 weeks
Study NCT01456780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B+L Advanced Eye Relief Lubricant Drop
Description: Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
Study NCT03155204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium pMDI
Description: inhalation
Study NCT03155204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium pMDI
Description: inhalation
Study NCT03881657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reverse Colocated Integrated Care
Description: A reverse colocated integrated care model is one where primary care and preventive services are embedded within a behavioral health service setting.
Study NCT03881657 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Behavioral health services without primary care or integrated care services
Study NCT02718443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXM01
Description: Oral immunotherapy targeting VEGFR2
Study NCT02107001 — intervention group
Intervention type: PROCEDURE
Intervention: Lung ultrasound
Description: Lung ultrasonography performed and interpreted by a physician (Pulmonologist or Emergency Physician) possessing specific knowledge in the procedure and a training of at least 100 thoracic ultrasonographies in accordance to a prespecified protocol.
Study NCT02197871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral nutrition emulsion
Description: The patient should drink the oral nutritional supplements according to the estimated energy intake and make a record everyday.The patients will be followed up regularly.
Study NCT04413279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow Thermal Pulsation
Description: To manage patients with dry eye disease secondary to MGD
Study NCT04413279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
Description: to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation
Study NCT02579512 — intervention group
Intervention type: OTHER
Intervention: Extra-corporeal ECG signal analysis
Description: The NIA algorithm is similar to the traditional 12-lead ECG equipment. By analyzing patient data, NIA algorithm provides more detailed results compared to traditional 12-lead ECG. Patients with suspected coronary artery disease are conventionally diagnosed and treated by cardiac catheterization. However, cardiac catheterization is invasive procedure. Unless clinical diagnosis is evident before cardiac catheterization, a treadmill exercise test, a nuclear medicine myocardial perfusion test, or a multi-direction coronary CT angiogram is usually performed to increase the accuracy of diagnosis. But these examinations are not accessible to all patients, and are time-consuming and costly.
Study NCT03511248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate-rich Beetroot Juice
Description: The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
Study NCT03511248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-deplete Beetroot Juice
Description: The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
Study NCT01473628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Observation
Description: Undergo observation
Study NCT01473628 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT01473628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT00002556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV
Study NCT00002556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00002556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine
Description: Given IV
Study NCT01493596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: An equal volume of water mixed with juice will be administered.
Study NCT00002556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV
Study NCT00002556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Description: Given PO
Study NCT00002556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given PO
Study NCT00002556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV
Study NCT00002556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00002556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Given PO
Study NCT00002556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT00002556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: Given SC
Study NCT00002556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00002556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03683472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unwinding Anxiety Phone App
Description: The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety
Study NCT02933320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-1206 single agent dose escalation phase
Description: BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.
Study NCT02933320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination of BI-1206 with rituximab escalation phase
Description: An investigation of combination treatment of BI-1206 with rituximab.
Study NCT01655446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation
Description: This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
Study NCT03423667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine (1200 mg) administered twice a day during 5 days
Study NCT03423667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose powder
Description: Placebo comparator.
Study NCT03182751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours
Study NCT03182751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Looks exactly like the study drug, but it contains no active ingredient
Study NCT00196820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT03324217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Practise
Description: They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.
Study NCT03324217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental Practise
Description: They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.
Study NCT01175473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily 30 minutes before breakfast.
Study NCT01175473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Study NCT01175473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Self administered by subcutaneous injections once daily 30 minutes before breakfast.
Study NCT01175473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-filled pen injector
Study NCT01175473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
Study NCT02933320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-1206 single agent expansion phase
Description: BI-1206 single agent expansion phase at the RP2D.
Study NCT01175473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
Study NCT03864185 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (genetical recombination)
Description: Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.
Study NCT03864185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer placebo IV infusion once weekly for 4 doses.
Study NCT01655446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation with FES
Description: This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.